Editorial: Diffuse proliferative lupus nephritis. Evaluation of therapy.
D000305:Adrenal Cortex Hormones / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D001379:Azathioprine / Q000627:therapeutic use; D002648:Child; D002986:Clinical Trials as Topic; D003520:Cyclophosphamide / Q000627:therapeutic use; D004341:Drug Evaluation; D004357:Drug Synergism; D004359:Drug Therapy, Combination; D006801:Humans; D007128:Immunoglobulin Fragments / Q000652:urine; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use; D008180:Lupus Erythematosus, Systemic / Q000188:drug therapy*; D009393:Nephritis / Q000188:drug therapy* / Q000401:mortality; D010919:Placebos; D011241:Prednisone / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D011446:Prospective Studies
D000305:Adrenal Cortex Hormones; D007128:Immunoglobulin Fragments; D007166:Immunosuppressive Agents; D010919:Placebos; D003520:Cyclophosphamide; D001379:Azathioprine; D011241:Prednisone